This randomized controlled trial will take place at approximately 20 sites across the United States and will enroll a maximum of 150 adult patients with moderate to severe OSA who do not achieve results from a traditional CPAP machine or have declined its use.
ZOLL, which has been a significant investor in Respicardia for more than 3 years, will welcome all Respicardia employees into its workforce.
UnitedHealthcare is one of the businesses of UnitedHealth Group, a diversified health care company that provides coverage for approximately 41 million members.
The agreement allows Nyxoah to further develop new neurostimulation technologies for the treatment of sleep-disordered breathing conditions that were invented by Vanderbilt’s David T. Kent, MD.
Read More‘Those who may need an MRI can benefit from Nyxoah’s innovations with no fear for themselves and their implant during the exam.’
Read More
Panelists discuss proper patient selection, preparation for device evaluation and the procedure, and post-implant adjustments.
Read More
Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the Respicardia Inc’s remedē System implantable therapy for central sleep apnea, effective immediately.
Read MoreThe implantation took place at the Nose and Sinus Institute Boca Raton, Fla, and was performed by Melyssa Hancock, MD.
Read MoreThe DREAM (Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea) study is a pivotal, Investigational Device Exemption trial designed to support the marketing authorization of the Genio system in the United States.
Read MoreThe trial seeks to explore whether transvenous stimulation can improve airway physiology.
Read More
Highlights from the 5-year data show sustained improvements that were consistent with the published 6-, 12-, 24-, and 36-month results.
Read More
After more than 20 years of troubled sleep, Dwight Johnson can finally sleep peacefully throughout the night.
Read MoreHealth plan provider Humana Inc will provide coverage for Inspire upper airway stimulation therapy, effective August 27.
Read MoreThe reimbursement process is anticipated to be completed during 2021 and Inspire expects to launch its therapy in Australia thereafter.
Read More
Physicians who use Inspire upper airway stimulation, Respicardia’s remedē, and Avery’s diaphragm pacemaker share their stories.
Read More
Positive airway pressure therapy isn’t for everyone, says AASM award winner Richard Berry, MD, FAASM, who also shares his insights on positional therapies, neurostimulation, and interface selection.
Read More
Inspire has multiple additional digital health solutions in development that are aimed at improving patient outcomes and medical practice efficiency.
Read MoreThe US Food and Drug Administration (FDA) has approved an expanded age range for Inspire Upper Airway Stimulation Therapy for obstructive sleep apnea to include 18-21 year old patients.
Read More